HQL News and Press, TeklaLife Sciences Investors From 12/14/21

I put some capital to work through the month of November in 5 different funds. Black Friday wasn't just a day for shoppers in physical stores, but with the stock market decline, investors got a chance to snag some values too. The Omicron variant of COVID puts uncertainty in the ma...

4 out of 24 CEF sectors positive on price and 2 out of 24 sectors positive on NAV last week. Date for PIMCO merger of PCI and PKO into PDI announced. USA rights offering results. JDD, JTA and JTD have been merged into the multi-asset NMAI. For further details see: We...

Tekla Life Sciences (NYSE:HQL) declares $0.42/share quarterly dividend, -2.3% decrease from prior dividend of $0.43. Forward yield 8.11% Payable Dec. 31; for shareholders of record Nov. 24; ex-div Nov. 23. See HQL Dividend Scorecard, Yield Chart, & Dividend Growth. For further details s...

Most investors are ignoring a clear shot at 7%+ dividends double-digit price gains—year in and year out—in a sector everyone should be talking about, but isn’t. That would be healthcare, which is riding a rocket of rising spending: according to the latest number...

Tekla Life Sciences Investors mainly invests in Biotechnology firms. It offers robust quarterly distribution to investors. The fund also invests in restricted securities in private and public companies. For further details see: Tekla Life Sciences Investors Rides Biotech...

August was quite the busy month for my closed-end fund portfolio, though 4 of the additions came about as swaps for better valued funds. DLY was a recent fund I covered, and is one that I swapped out from PKO, but I also added additional capital. I sold out two funds in August but...

We’ve seen economic data in recent months moderate after record growth in the first half of 2021. In financials, the rise of many fintech companies and the growth of digital payments has really disrupted the traditional banking industry, creating new options for consumers. ...

Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...

Last year, we were looking at distribution changes due to the COVID pandemic sell-off. CEFs distribute out most of their earnings as distributions, so they pay relatively higher yields. However, relatively higher yields mean that any downturn is likely to cause distribution cuts. ...

In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...